Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Predict cytogenetic abnormalities with gene expression profiles

ABSTRACT: Cytogenetic abnormalities (CA) are important clinical parameters in various types of cancer, including multiple myeloma (MM). We developed a model to predict CA in patients with MM using gene expression profiling (GEP) and validated it by different cytogenetic techniques. The model was shown to have an accuracy up to 0.89. These results provide proof of concept for the hypothesis that GEP could serve as a one-stop data source for clinical molecular diagnosis and/or prognosis.

ORGANISM(S): Homo sapiens

PROVIDER: GSE29023 | GEO | 2012/06/12

SECONDARY ACCESSION(S): PRJNA140477

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Predict cytogenetic abnormalities with gene expression profiles

Project description:Cytogenetic abnormalities (CA) are important clinical parameters in various types of cancer, including multiple myeloma (MM). We developed a model to predict CA in patients with MM using gene expression profiling (GEP) and validated it by different cytogenetic techniques. The model was shown to have an accuracy up to 0.89. These results provide proof of concept for the hypothesis that GEP could serve as a one-stop data source for clinical molecular diagnosis and/or prognosis. 92 paired RNA-DNA samples were hybridized to Affy U133Plus2 and Agilent 244K aCGH arrays and used as training set. Another 23 paired samples as test set.

2012-06-11 | E-GEOD-29023 | biostudies-arrayexpress

EXPRESSION SIGNATURE TO PREDICT MAJOR CYTOGENETIC RESPONSE IN CHRONIC PHASE CML PATIENTS TREATED WITH IMATINIB

Project description:Newly diagnosed chronic phase chronic myeloid leukemia (CML) patients with a major cytogenetic response (MCyR) after 12 months of imatinib therapy have an excellent long-term outcome, while patients without MCyR have a high progression risk. Since patients with primary cytogenetic resistance may benefit from more intensive therapy up-front, we sought to identify biomarkers to predict MCyR. Keywords: Two group comparison to identify trasncriptomic signature that predicts response to therapy

2010-01-01 | GSE14671 | GEO

Expression data from meningiomas and normal meninges

Project description:Correlate the gene expression profiles with the most relevant patterns of chromosome abnormalities (cytogenetic subgroups of meningiomas) and the gene expression profiles could help to explain the differences in clinical behaviour of meningiomas. The impact of tumor cytogenetics on the gene expression analyzed in meningiomas. Here, we analyzed the gene expression profiles (GEP) of 47 tumors and correlated them with the most clinical relevant cytogenetic subgroups of meningiomas, including diploid tumors, isolated -22/22q-, del(1p36) alone and complex karyotypes associated with del(1p36) and/or -14q. In addition, 4 samples containing purified RNA extracted from normal meningeal cells (BioChain Institute, Hayward, CA and US Biological, Swampscott, MA, USA) were also processed.

2013-01-05 | E-GEOD-43290 | biostudies-arrayexpress

SNP genotyping of cryptic complexity in structural chromosome abnormalities previously detected by cytogenetic analysis

Project description:Purpose: The purpose of this study was to evaluate SNP genotyping methodology as a means to detect chromosomal abnormalities previously diagnosed by G-band karyotype or fluorescence in situ hybridization (FISH) analysis and to determine the frequency of sub-microscopic (cryptic) chromosomal alterations in these subjects. Methods: We used the Illumina HumanHap Beadchip platform to genotype 40 individuals having previously detected chromosomal anomalies (by G-banded and/or FISH analysis). The resulting data were analyzed for signal intensity (log R ratio) and allelic composition (B allele frequency). Results: SNP array analysis detected 100% of previously identified cytogenetic abnormalities. Changes or clarifications of the ISCN karyotype designation assigned by conventional cytogenetic and/or FISH analysis were made in 82 % of the cases (32 of 39). Nine of the 39 cases (23%) involved a reassignment of an abnormal band while an additional 9 of the 39 (23%) resulted in a clarification of a sub-band assignment. In 8 more of the 39 cases (21%) the previously reported alterations were confirmed, however the SNP analysis also identified related cryptic alterations. SNP analysis not only confirmed FISH-detected abnormalities but also more precisely mapped the breakpoints of 6/6 patients. Investigations into the origin of de novo abnormalities in 15 trio families established that 12 /15 occurred on the paternal chromosome. Conclusions: SNP genotyping array analysis, confirmed all previously detected structural chromosomal abnormalities and provided additional, clinically-relevant genomic information in 82% of these alterations.

2011-02-22 | GSE20623 | GEO

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech center experience

Project description:In this paper, we demonstrated the possibility of effective utilization of oligonucleotide-based aCGH as a robust clinical tool for genome-wide scanning and detailed analysis of unbalanced genetic aberrations in 91 MM patients in combination with fluorescence in situ hybridization (FISH) in detection of high risk chromosomal aberrations. Loss of TP53 gene, translocation t(4;14)(p16;q32), gain in 1q21 and non-hyperdiploidy (non-hyperdiploid) area are associated with adverse prognosis in MM, thus their evaluation with other lesions obtained via genomic profiling could lead to better classification and risk assesment for thr patients.

2014-04-01 | E-MTAB-1792 | biostudies-arrayexpress

SNP genotyping of cryptic complexity in structural chromosome abnormalities previously detected by cytogenetic analysis

2011-02-22 | E-GEOD-20623 | biostudies-arrayexpress

Third Generation Cytogenetic Analysis

Project description:Third Generation Cytogenetic Analysis (TGCA): diagnostic application of long-read sequencing

| PRJEB46928 | ENA

Circular RNAs to predict clinical outcome after cardiac arrest

Project description:Background: Cardiac arrest (CA) represents the third leading cause of death worldwide. Among survivors, severe neurological sequelae are frequent but difficult to predict. Novel prognostic biomarkers would offer clinicians the possibility to deliver personalized healthcare. The potential of small circulating noncoding RNAs (microRNAs) to predict neurological outcome and survival after CA has been reported. Objective: This study aims to identify circulating circular RNAs (circRNAs) associated with clinical outcome after CA. Methods and Results: Methods and Results: Whole blood samples obtained 48h after return of spontaneous circulation from 23 sex-matched survivors and 23 deceased cardiac arrest (CA) patients were enrolled in this study. Whole transcriptome RNA sequencing identified candidate RNAs associated with neurological outcome and survival. Conclusion: We have identified candidate RNAs associated with clinical outcome after CA whose predictive value remains to be confirmed in large populations.

2022-11-02 | GSE197764 | GEO

Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure

Project description:In vivo changes of gene expression profiles (GEP) of tumor cells 48hr after single agent therapy may vary by treatment and provide added predictive power over baseline GEP information. In newly diagnosed patients with multiple myeloma (MM), GEP data were obtained on tumor cells prior to and 48hr after dexamethasone (n=45) or thalidomide treatment (n=42); in case of relapsed MM, GEP data were obtained prior to (n=36) and after (n=19) lenalidomide administration. Dexamethasone and thalidomide induced both common and unique GEP changes. Combined baseline and 48hr changes of GEP in a subset of genes that were discovered in newly diagnosed MM also predicted event-free and overall survival in relapsed patients receiving lenalidomide. Combined with baseline molecular features, changes in GEP following short-term single agent treatment may help guide treatment decisions for patients with MM. The genes whose altered expression is related to eventual survival may also point to mechanisms of action and resistance to different classes of drugs. Keywords: drug response

2008-08-04 | GSE8546 | GEO

Cytogenetic aberrations in Hepatocellular adenoma and carcinoma

Project description:Cytogenetic aberrations in Hepatocellular adenoma and carcinoma

| PRJNA266614 | ENA